• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Globus Medical extends versatility of Advanced Materials Science™ anterior interbody portfolio with launch of COHERE™ ALIF Spacer and Modulus™ ALIF Blades

    3/11/25 4:40:00 PM ET
    $GMED
    Medical/Dental Instruments
    Health Care
    Get the next $GMED alert in real time by email

    AUDUBON, Pa., March 11, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal technology company, today announced two commercial launches:

    1. COHERE™ ALIF Spacer: The first Porous PEEK™ interbody spacer for anterior lumbar interbody fusion (ALIF) surgery, and
    2. Modulus™ ALIF Blades: An extension of the market-leading Modulus™ ALIF interbody spacer system.

    The COHERE ™ ALIF Spacer is the latest addition to Globus Medical's Advanced Materials Science™ (AMS) implant portfolio, featuring proprietary porous surface technology designed for bone in-growth while maintaining the imaging and mechanical properties favored in a solid PEEK interbody spacer.1,2

    "Porous PEEK combines the stiffness and radiolucency of PEEK with the osseointegration potential offered by the porous technology,"1,3 said Frank Phillips, MD, professor of orthopedic surgery and fellowship director of the Division of Spine Surgery at Rush University Medical Center in Chicago. "The enhanced clinical outcomes possible with Cohere™ Porous PEEK for anterior cervical fusion4 and the comprehensive surface technology options available are now also helping to advance patient care for anterior lumbar spine surgery. In addition, the ability to radiographically assess fusion is a significant clinical benefit."

    Modulus™ ALIF Blades extend the versatility of the Modulus™ ALIF Spacer portfolio by offering surgeons different fixation options with the same interbody spacer. Procedural efficiency is achieved with Modulus™ ALIF Blades through the ability to deliver anchoring blade fixation immediately following interbody spacer placement to reduce the number of surgical steps and instruments needed in the procedure. 

    "Modulus™ ALIF with the anchoring blade option makes anterior spine surgery even more efficient while potentially reducing complications by reducing the number of instrument passes adjacent to major vessels," said Anthony Kwon, MD, Orthopedic Spine Surgeon practicing at OrthoCarolina's Spine Center and Atrium Medical Center in Charlotte, NC. "The low-profile instrumentation and streamlined delivery of fixation also helps to reduce the exposure window traditionally needed for anterior surgery, allowing for a more minimally invasive approach".

    These two new offerings strengthen Globus Medical's comprehensive anterior spine portfolio, designed to address a variety of the most challenging procedures in spine surgery. The integration of a Porous PEEK interbody spacer option and Modulus anchor fixation demonstrate Globus Medical's commitment to providing surgeon partners with procedurally integrated ALIF solutions.

    "These products underscore our commitment to advancing surgical outcomes and providing spine surgeons with best-in-class solutions that span varying patient anatomy and surgeon preference to provide the best possible care in their hands," said David Hole, president of Spine at Globus Medical. "We remain dedicated to delivering innovation through our product development engine to solve the unmet clinical needs of our surgeon partners while helping to improve patient care."

    About Globus Medical, Inc.

    Globus Medical, Inc. is a leading global musculoskeletal company dedicated to solving unmet clinical needs and changing lives. We innovate with inspired urgency, provide world-class education and clinical support, and advance care throughout spine, orthopedic trauma, joint reconstruction, biomaterials and enabling technologies. Additional information can be accessed at https://www.globusmedical.com/.



    References:

    1. Evans NT, Torstrick FB, Lee CS, et al. High-strength, surface-porous polyether-ether-ketone for load-bearing orthopedic implants. Acta Biomater 2015;13:159-67.

    2. Torstrick FB, Lin ASP, Potter D, et al. Porous PEEK improves the bone-implant interface compared to plasma-sprayed titanium coating on PEEK. Biomaterials 2018;185:106-16

    3. Torstrick FB, Evans NT, Stevens HY, et al. Do surface porosity and pore size influence mechanical properties and cellular response to PEEK? Clin Orthop Relat Res 2016;474(11):2373-83.

    4. Hill CP and Strenge KB. Early clinical outcomes comparing porous PEEK, smooth PEEK, and structural allograft interbody devices for anterior cervical discectomy and fusion. J Spine Neurosurg 2019;8(1):1-7.

    Safe Harbor Statements 

    All statements included in this press release other than statements of historical fact are forward-looking statements and may be identified by their use of words such as "believe," "may," "might," "could," "will," "aim," "estimate," "continue," "anticipate," "intend," "expect," "plan" and other similar terms. These forward-looking statements are based on our current assumptions, expectations and estimates of future events and trends. Forward-looking statements are only predictions and are subject to many risks, uncertainties and other factors that may affect our businesses and operations and could cause actual results to differ materially from those predicted. These risks and uncertainties include, but are not limited to, the risks and costs associated with the integration of, and the ability of Globus Medical and NuVasive to integrate, their businesses successfully and to achieve anticipated synergies, health epidemics, pandemics and similar outbreaks, including the COVID-19 pandemic, factors affecting our quarterly results, our ability to manage our growth, our ability to sustain our profitability, demand for our products, our ability to compete successfully (including without limitation our ability to convince surgeons to use our products and our ability to attract and retain sales and other personnel), our ability to rapidly develop and introduce new products, our ability to develop and execute on successful business strategies, our ability to comply with laws and regulations that are or may become applicable to our businesses, our ability to safeguard our intellectual property, our success in defending legal proceedings brought against us, trends in the medical device industry, general economic conditions, and other risks. For a discussion of these and other risks, uncertainties and other factors that could affect our results, you should refer to the disclosure contained in our most recent annual report on Form 10-K filed with the Securities and Exchange Commission, including the sections labeled "Risk Factors" and "Cautionary Note Concerning Forward-Looking Statements," and in our Forms 10-Q, Forms 8-K and other filings with the Securities and Exchange Commission. These documents are available at www.sec.gov. Moreover, we operate in an evolving environment. New risk factors and uncertainties emerge from time to time and it is not possible for us to predict all risk factors and uncertainties, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Given these risks and uncertainties, readers are cautioned not to place undue reliance on any forward-looking statements. Forward-looking statements contained in this press release speak only as of the date of this press release. We undertake no obligation to update any forward-looking statements as a result of new information, events or circumstances or other factors arising or coming to our attention after the date hereof.

    Investor contact:

    Brian Kearns

    610-930-1800

    [email protected]

    Media contact:

    Moran Chavez

    [email protected]



    Primary Logo

    Get the next $GMED alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $GMED

    DatePrice TargetRatingAnalyst
    1/10/2025$97.00Underperform → Neutral
    BofA Securities
    12/2/2024$83.00 → $100.00Equal-Weight → Overweight
    Morgan Stanley
    8/7/2024$60.00 → $78.00Equal Weight → Overweight
    Wells Fargo
    5/20/2024$60.00 → $80.00Neutral → Overweight
    Piper Sandler
    3/18/2024$60.00Neutral → Buy
    BTIG Research
    10/20/2023$75.00Buy
    ROTH MKM
    9/19/2023$61.00Hold → Buy
    Stifel
    3/30/2023$67.00Hold → Buy
    Canaccord Genuity
    More analyst ratings

    $GMED
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Globus Medical Reports First Quarter 2025 Results

      AUDUBON, Pa., May 08, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, today announced its financial results for the quarter ended March 31, 2025. Worldwide net sales were $598.1 million, a decrease of 1.4%, or a decrease of 0.8% on a constant currency basisGAAP net income for the quarter was $75.5 millionGAAP diluted earnings per share ("EPS") was $0.54 and non-GAAP diluted EPS was $0.68 "Our first quarter results were impacted by softer Enabling Technology deal closures, temporary integration related supply chain disruption, and timing of international distributor orders, partially offset by strength in our core US spine busine

      5/8/25 4:15:00 PM ET
      $GMED
      Medical/Dental Instruments
      Health Care
    • Globus Medical Schedules First Quarter Earnings Release and Conference Call

      AUDUBON, Pa., April 17, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal technology company, will announce its financial results for the first quarter ended March 31, 2025 after the market close on Thursday, May 8, 2025. A copy of the release will be available on the Globus Medical website at www.investors.globusmedical.com. Following the announcement, Globus Medical will hold a teleconference to discuss its performance with the investment community at 4:30 p.m. Eastern Time. Participants may access the conference call live via webcast on the Investors page of Globus Medical's website at https://www.investors.globusmedical.com/news-events/events-webcast

      4/17/25 4:30:00 PM ET
      $GMED
      Medical/Dental Instruments
      Health Care
    • Globus Medical completes acquisition of Nevro Corp.

      AUDUBON, Pa., April 03, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal technology company, today announced the completion of its previously disclosed acquisition of Nevro Corp., a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain. "We are excited to begin the journey of accelerating market penetration of Nevro's differentiated high-frequency technology and bringing a much-needed treatment option to patients suffering from chronic pain," said Dan Scavilla, president and CEO of Globus Medical. The acquisition of Nevro further expands Globus Medical's presence in the musculoskeletal

      4/3/25 8:31:24 AM ET
      $GMED
      Medical/Dental Instruments
      Health Care

    $GMED
    SEC Filings

    See more
    • SEC Form 10-Q filed by Globus Medical Inc.

      10-Q - GLOBUS MEDICAL INC (0001237831) (Filer)

      5/8/25 5:19:05 PM ET
      $GMED
      Medical/Dental Instruments
      Health Care
    • Globus Medical Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - GLOBUS MEDICAL INC (0001237831) (Filer)

      5/8/25 4:16:28 PM ET
      $GMED
      Medical/Dental Instruments
      Health Care
    • SEC Form DEFA14A filed by Globus Medical Inc.

      DEFA14A - GLOBUS MEDICAL INC (0001237831) (Filer)

      4/25/25 4:24:50 PM ET
      $GMED
      Medical/Dental Instruments
      Health Care

    $GMED
    Financials

    Live finance-specific insights

    See more
    • Globus Medical Reports First Quarter 2025 Results

      AUDUBON, Pa., May 08, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, today announced its financial results for the quarter ended March 31, 2025. Worldwide net sales were $598.1 million, a decrease of 1.4%, or a decrease of 0.8% on a constant currency basisGAAP net income for the quarter was $75.5 millionGAAP diluted earnings per share ("EPS") was $0.54 and non-GAAP diluted EPS was $0.68 "Our first quarter results were impacted by softer Enabling Technology deal closures, temporary integration related supply chain disruption, and timing of international distributor orders, partially offset by strength in our core US spine busine

      5/8/25 4:15:00 PM ET
      $GMED
      Medical/Dental Instruments
      Health Care
    • Globus Medical Schedules First Quarter Earnings Release and Conference Call

      AUDUBON, Pa., April 17, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal technology company, will announce its financial results for the first quarter ended March 31, 2025 after the market close on Thursday, May 8, 2025. A copy of the release will be available on the Globus Medical website at www.investors.globusmedical.com. Following the announcement, Globus Medical will hold a teleconference to discuss its performance with the investment community at 4:30 p.m. Eastern Time. Participants may access the conference call live via webcast on the Investors page of Globus Medical's website at https://www.investors.globusmedical.com/news-events/events-webcast

      4/17/25 4:30:00 PM ET
      $GMED
      Medical/Dental Instruments
      Health Care
    • Nevro Reports Fourth-Quarter and Full-Year 2024 Financial Results

      REDWOOD CITY, Calif., March 4, 2025 /PRNewswire/ -- Nevro Corp. (NYSE:NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today reported its fourth-quarter and full-year 2024 financial results. "We are pleased that adjusted EBITDA for the full-year 2024 came in ahead of our revised expectations and that our balance sheet remains strong, reflecting our ongoing focus on working capital management and the benefits from our 2024 restructurings," said Kevin Thornal, Nevro's president and CEO. "Importantly, we look forward to joining forces with Globus Medical to achieve our full potential and working together to free

      3/4/25 4:15:00 PM ET
      $GMED
      $NVRO
      Medical/Dental Instruments
      Health Care

    $GMED
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Globus Medical upgraded by BofA Securities with a new price target

      BofA Securities upgraded Globus Medical from Underperform to Neutral and set a new price target of $97.00

      1/10/25 8:55:48 AM ET
      $GMED
      Medical/Dental Instruments
      Health Care
    • Globus Medical upgraded by Morgan Stanley with a new price target

      Morgan Stanley upgraded Globus Medical from Equal-Weight to Overweight and set a new price target of $100.00 from $83.00 previously

      12/2/24 6:57:12 AM ET
      $GMED
      Medical/Dental Instruments
      Health Care
    • Globus Medical upgraded by Wells Fargo with a new price target

      Wells Fargo upgraded Globus Medical from Equal Weight to Overweight and set a new price target of $78.00 from $60.00 previously

      8/7/24 6:47:39 AM ET
      $GMED
      Medical/Dental Instruments
      Health Care

    $GMED
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Globus Medical Inc. (Amendment)

      SC 13G/A - GLOBUS MEDICAL INC (0001237831) (Subject)

      2/14/24 4:08:54 PM ET
      $GMED
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Globus Medical Inc. (Amendment)

      SC 13G/A - GLOBUS MEDICAL INC (0001237831) (Subject)

      2/13/24 5:06:16 PM ET
      $GMED
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Globus Medical Inc. (Amendment)

      SC 13G/A - GLOBUS MEDICAL INC (0001237831) (Subject)

      2/13/24 4:05:32 PM ET
      $GMED
      Medical/Dental Instruments
      Health Care

    $GMED
    Leadership Updates

    Live Leadership Updates

    See more
    • Dentsply Sirona Appoints Michael Barber and Daniel Scavilla as New Board Members

      CHARLOTTE, N.C., Feb. 06, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) today announced that Michael J. Barber and Daniel T. Scavilla have been appointed to its Board of Directors (the "Board"), effective February 5, 2025. Mr. Barber brings over 40 years of experience in product management and innovation, including executive leadership roles at GE, where he was responsible for the transformation of the company's digital X-Ray program. Mr. Scavilla, currently CEO of Globus Medical, is a seasoned executive with a deep skillset in commercial deployment and business integration, having successfully led the merger of Globus and NuVasive. Mr. B

      2/6/25 8:30:00 AM ET
      $EXAS
      $GE
      $GMED
      $XRAY
      Medical Specialities
      Health Care
      Consumer Electronics/Appliances
      Technology
    • IMPULSE DYNAMICS APPOINTS FIVE NEW BOARD MEMBERS

      MARLTON, N.J., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Impulse Dynamics N.V., a company dedicated to improving the lives of people with heart failure (HF), today announced the election of five new members to its Board of Directors at the most recent meeting of its shareholders.  "We are extremely pleased to have Jim Tobin, Joe Capper, Glenn Muir, John Bakewell, and Dan Scavila all joining our board of directors," said Prof. Shlomo Ben-Haim, Chairman of the Board and Founder of Impulse Dynamics.  "This is an illustrious group to be adding to the board, and I am extremely pleased to be welcoming and working with all of them as we rapidly advance our goals for the company, for CCM therapy, and mo

      11/11/21 7:26:31 PM ET
      $BEAT
      $GMED
      $GTHX
      $HOLX
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Medical Electronics
    • Axonics® Announces Appointment of David M. Demski to Board of Directors

      IRVINE, Calif.--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc. (Nasdaq: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction, today announced the appointment of veteran medical technology industry executive David M. Demski to its board of directors, effective January 1, 2021. Mr. Demski currently serves as president and CEO of Globus Medical, Inc. (Nasdaq: GMED), a publicly traded medical technology company that manufactures and markets musculoskeletal implants and related surgical products, with sales in 2019 of over $750 million and a curren

      12/14/20 8:00:00 AM ET
      $AXNX
      $GMED
      Medical/Dental Instruments
      Health Care

    $GMED
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Davidar David D

      4 - GLOBUS MEDICAL INC (0001237831) (Issuer)

      3/28/25 7:18:17 PM ET
      $GMED
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Director Deford John A

      4 - GLOBUS MEDICAL INC (0001237831) (Issuer)

      3/28/25 7:15:42 PM ET
      $GMED
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Director Douglas Robert Andrew

      4 - GLOBUS MEDICAL INC (0001237831) (Issuer)

      3/28/25 7:13:33 PM ET
      $GMED
      Medical/Dental Instruments
      Health Care